Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference

Rhea-AI Summary

Disc Medicine, a clinical-stage biopharmaceutical company, will participate in the H.C. Wainwright BioConnect Investor Conference on May 20th. The company focuses on developing treatments for hematologic diseases. The event will feature a fireside chat available via live webcast and archived replay on the company's website.

News Market Reaction – IRON

+2.14%

+2.14% Session move

In the trading session that priced this news, IRON gained 2.14%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WATERTOWN, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Monday, May 20^th at 10:30 am ET.

A live webcast of the fireside chat will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after the event.

About Disc

Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.

Media Contact

Peg Rusconi
Verge Scientific Communications
prusconi@vergescientific.com

Investor Relations Contact

Christina Tartaglia
Stern Investor Relations
christina.tartaglia@sternir.com

FAQ

When will Disc Medicine participate in the H.C. Wainwright BioConnect Investor Conference?

Disc Medicine will participate in the H.C. Wainwright BioConnect Investor Conference on Monday, May 20th at 10:30 am ET.

What is the focus of Disc Medicine's treatments?

Disc Medicine focuses on developing novel treatments for patients suffering from serious hematologic diseases.

Where can the fireside chat be accessed?

The fireside chat will be available through the investor relations section of Disc Medicine's website at ir.discmedicine.com.